US20200123227A1
University of Texas System
The present disclosure is directed to interferon prodrugs and their use in treating cancer. A particular advantage to such constructs is their ability to exert powerful anti-tumor activity in vivo reduction in many of the significant toxicities associated with interferon therapy.